Takeda Pharmaceutical Co Ltd
TAK15.025USD
-0.084-0.56%
Close 04/25, 16:00（ET）Quotes delayed by 15 min
23.82BMarket Cap
0.11P/E TTM
More Details of Takeda Pharmaceutical Co Ltd Company
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
Company Info
Company codeTAK
Company nameTakeda Pharmaceutical Co Ltd
IPO dateMay 16, 1949
Founded at1925
CEOMr. Christophe Weber
Number of employees49281
Security typeDepository Receipt
Fiscal year-endMay 16
Address4F
CityCHUO-KU
Stock exchangeNYSE Consolidated
CountryJapan
Postal code103-8668
Phone81332782111
Websitehttps://www.takeda.com/
Company codeTAK
IPO dateMay 16, 1949
Founded at1925
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
8.26K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
1.38K
-85.30%
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Miki Tsusaka
Ms. Miki Tsusaka
Independent Director
Independent Director
--
--
Mr. Koji Hatsukawa
Mr. Koji Hatsukawa
Independent Director
Independent Director
--
--
Mr. Milano Furuta
Mr. Milano Furuta
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. Masami Iijima
Mr. Masami Iijima
Chairman of Board of Directors, Independent Director
Chairman of Board of Directors, Independent Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
8.26K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
1.38K
-85.30%
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Miki Tsusaka
Ms. Miki Tsusaka
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: JPYUpdate time: Sun, Apr 6
Currency: JPYUpdate time: Sun, Apr 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
FY2019
By BusinessJPY
Name
Revenue
Proportion
Gastrointestinal diseases
344.12B
30.08%
Plasma derivatives
248.54B
21.72%
Rare diseases
190.32B
16.63%
Oncology
143.10B
12.51%
Neuroscience
141.94B
12.41%
Other
76.15B
6.66%
By RegionJPY
Name
Revenue
Proportion
United States
593.84B
51.90%
Europe And Canada (Country)
262.60B
22.95%
Japan
108.34B
9.47%
Asia
69.19B
6.05%
Latin America
58.66B
5.13%
Other
51.53B
4.50%
By Business
By Region
By BusinessJPY
Name
Revenue
Proportion
Gastrointestinal diseases
344.12B
30.08%
Plasma derivatives
248.54B
21.72%
Rare diseases
190.32B
16.63%
Oncology
143.10B
12.51%
Neuroscience
141.94B
12.41%
Other
76.15B
6.66%
Shareholder
Update time: Tue, Apr 8
Update time: Tue, Apr 8
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.16%
Arrowstreet Capital, Limited Partnership
0.14%
Fidelity Management & Research Company LLC
0.11%
First Trust Advisors L.P.
0.10%
Other
99.07%
Shareholder Statistics
Shareholder
Proportion
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.16%
Arrowstreet Capital, Limited Partnership
0.14%
Fidelity Management & Research Company LLC
0.11%
First Trust Advisors L.P.
0.10%
Other
99.07%
Type
Shareholder
Proportion
Investment Advisor
1.55%
Investment Advisor/Hedge Fund
0.35%
Hedge Fund
0.27%
Research Firm
0.14%
Family Office
0.01%
Family Office
0.01%
Family Office
0.01%
Other
97.64%
Institutional Shareholding
Update time: Sun, Jan 19
Update time: Sun, Jan 19
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
574
73.02M
2.32%
-10.12M
2024Q4
595
73.56M
2.33%
-9.88M
2024Q3
583
77.60M
2.45%
-3.33M
2024Q2
581
73.43M
2.34%
-14.54M
2024Q1
593
78.98M
2.52%
-11.62M
2023Q4
609
83.80M
2.67%
-18.91M
2023Q3
621
81.24M
2.59%
-37.59M
2023Q2
617
84.64M
2.72%
-34.14M
2023Q1
627
84.81M
2.73%
-21.74M
2022Q4
637
69.93M
2.25%
-40.01M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Capital Research Global Investors
13.16M
0.42%
+25.31K
+0.19%
Dec 31, 2024
Parametric Portfolio Associates LLC
5.14M
0.16%
+961.51K
+23.02%
Dec 31, 2024
Arrowstreet Capital, Limited Partnership
4.22M
0.13%
-419.02K
-9.04%
Dec 31, 2024
Fidelity Management & Research Company LLC
3.33M
0.11%
+438.69K
+15.18%
Dec 31, 2024
First Trust Advisors L.P.
3.24M
0.1%
+62.72K
+1.97%
Dec 31, 2024
Renaissance Technologies LLC
3.08M
0.1%
-139.40K
-4.33%
Dec 31, 2024
Brandes Investment Partners, L.P.
3.04M
0.1%
-192.02K
-5.94%
Dec 31, 2024
Goldman Sachs Asset Management, L.P.
2.32M
0.07%
+131.24K
+6.01%
Dec 31, 2024
Van Eck Associates Corporation
2.21M
0.07%
+35.19K
+1.62%
Dec 31, 2024
Aperio Group, LLC
2.20M
0.07%
+313.03K
+16.56%
Dec 31, 2024
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
VanEck Pharmaceutical ETF
4.7%
SGI Enhanced Global Income ETF
3.05%
Roundhill GLP-1 & Weight Loss ETF
2.1%
ActivePassive International Equity ETF
0.6%
First Trust Value Line Dividend Index Fund
0.45%
Pacer Trendpilot International ETF
0.26%
Avantis International Equity ETF
0.07%
Avantis Responsible International Equity ETF
0.07%
DFA Dimensional International Core Equity 2 ETF
0%
Pacer Developed Markets International Cash Cws 100
0%
View more
VanEck Pharmaceutical ETF
Proportion4.7%
SGI Enhanced Global Income ETF
Proportion3.05%
Roundhill GLP-1 & Weight Loss ETF
Proportion2.1%
ActivePassive International Equity ETF
Proportion0.6%
First Trust Value Line Dividend Index Fund
Proportion0.45%
Pacer Trendpilot International ETF
Proportion0.26%
Avantis International Equity ETF
Proportion0.07%
Avantis Responsible International Equity ETF
Proportion0.07%
DFA Dimensional International Core Equity 2 ETF
Proportion0%
Pacer Developed Markets International Cash Cws 100
Proportion0%
Dividend
A total of
1.42T
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Sep 12, 2024
TAK.NB Final Cash Dividend of gross USD 0.326079 paid on Dec 12, 2024 going ex on Sep 30, 2024
Sep 30, 2024
Dec 12, 2024
Sep 30, 2024
Mar 14, 2024
TAK.NB Interim Cash Dividend of gross USD 0.292214 paid on Jul 08, 2024 going ex on Mar 27, 2024
Mar 28, 2024
Jul 08, 2024
Mar 27, 2024
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data